Anila Lingamneni Sells 2,305 Shares of Haemonetics Co. (NYSE:HAE) Stock

Haemonetics Co. (NYSE:HAE) EVP Anila Lingamneni sold 2,305 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $95.00, for a total transaction of $218,975.00. Following the completion of the transaction, the executive vice president now owns 12,295 shares in the company, valued at $1,168,025. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Haemonetics Trading Down 0.7 %

NYSE HAE opened at $92.59 on Friday. The company has a market capitalization of $4.70 billion, a PE ratio of 37.64, a P/E/G ratio of 2.23 and a beta of 0.34. The stock has a 50-day simple moving average of $83.98 and a 200 day simple moving average of $82.88. The company has a current ratio of 2.92, a quick ratio of 1.76 and a debt-to-equity ratio of 0.91. Haemonetics Co. has a 12 month low of $70.74 and a 12 month high of $97.13.

Haemonetics (NYSE:HAE) last issued its quarterly earnings data on Thursday, February 8th. The medical instruments supplier reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.10. The firm had revenue of $336.20 million during the quarter, compared to analysts’ expectations of $320.84 million. Haemonetics had a net margin of 9.97% and a return on equity of 22.37%. The business’s revenue for the quarter was up 10.1% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.85 earnings per share. Research analysts forecast that Haemonetics Co. will post 3.95 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have weighed in on HAE. StockNews.com cut shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TheStreet cut shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Finally, Barrington Research restated an “outperform” rating and issued a $105.00 price objective on shares of Haemonetics in a report on Friday, April 12th.

Institutional Trading of Haemonetics

A number of large investors have recently made changes to their positions in the company. Carmel Capital Partners LLC bought a new position in shares of Haemonetics during the 3rd quarter valued at about $30,000. TFO Wealth Partners LLC lifted its stake in Haemonetics by 29,450.0% in the fourth quarter. TFO Wealth Partners LLC now owns 591 shares of the medical instruments supplier’s stock valued at $51,000 after buying an additional 589 shares in the last quarter. Group One Trading L.P. acquired a new position in shares of Haemonetics in the third quarter valued at approximately $55,000. Parkside Financial Bank & Trust increased its position in shares of Haemonetics by 17.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 1,054 shares of the medical instruments supplier’s stock worth $90,000 after acquiring an additional 156 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in shares of Haemonetics during the first quarter worth $114,000. Institutional investors own 99.67% of the company’s stock.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.